May 4, 2022

For patients with recurrent cervical cancer after first-line platinum-containing chemotherapy, survival is significantly longer with cemiplimab than with single-agent chemotherapy, according to a study published in the Feb. 10 issue of the New England Journal of Medicine. Krishnansu S. Tewari, M.D., from the University of California in Irvine, and colleagues enrolled patients with recurrent cervical cancer...